Literature DB >> 26762834

Allosteric inhibitors of Coxsackie virus A24 RNA polymerase.

Catherine H Schein1, Diane Rowold2, Kyung H Choi3.   

Abstract

Coxsackie virus A24 (CVA24), a causative agent of acute hemorrhagic conjunctivitis, is a prototype of enterovirus (EV) species C. The RNA polymerase (3D(pol)) of CVA24 can uridylylate the viral peptide linked to the genome (VPg) from distantly related EV and is thus, a good model for studying this reaction. Once UMP is bound, VPgpU primes RNA elongation. Structural and mutation data have identified a conserved binding surface for VPg on the RNA polymerase (3D(pol)), located about 20Å from the active site. Here, computational docking of over 60,000 small compounds was used to select those with the lowest (best) specific binding energies (BE) for this allosteric site. Compounds with varying structures and low BE were assayed for their effect on formation of VPgU by CVA24-3D(pol). Two compounds with the lowest specific BE for the site inhibited both uridylylation and formation of VPgpolyU at 10-20μM. These small molecules can be used to probe the role of this allosteric site in polymerase function, and may be the basis for novel antiviral compounds.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  +-Strand RNA virus; Antiviral compounds; Coxsackie virus; Docking compound libraries; Enterovirus RNA polymerase; Poliovirus; Protein-primed RNA synthesis; Uridylylation mechanism

Mesh:

Substances:

Year:  2015        PMID: 26762834      PMCID: PMC4743507          DOI: 10.1016/j.bmc.2015.12.023

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  60 in total

1.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

2.  Allosteric effects of ligands and mutations on poliovirus RNA-dependent RNA polymerase.

Authors:  Joanna E Boerner; John M Lyle; Sarah Daijogo; Bert L Semler; Stephen C Schultz; Karla Kirkegaard; Oliver C Richards
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis.

Authors:  William G Flight; Rowland J Bright-Thomas; Peter Tilston; Kenneth J Mutton; Malcolm Guiver; Julie Morris; A Kevin Webb; Andrew M Jones
Journal:  Thorax       Date:  2013-10-14       Impact factor: 9.139

4.  Protein-primed RNA synthesis by purified poliovirus RNA polymerase.

Authors:  A V Paul; J H van Boom; D Filippov; E Wimmer
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

5.  Studies with poliovirus polymerase 3Dpol. Stimulation of poly(U) synthesis in vitro by purified poliovirus protein 3AB.

Authors:  A V Paul; X Cao; K S Harris; J Lama; E Wimmer
Journal:  J Biol Chem       Date:  1994-11-18       Impact factor: 5.157

6.  Anti-VPg antibody inhibition of the poliovirus replicase reaction and production of covalent complexes of VPg-related proteins and RNA.

Authors:  M H Baron; D Baltimore
Journal:  Cell       Date:  1982-10       Impact factor: 41.582

7.  Genome-linked protein VPg of poliovirus is present as free VPg and VPg-pUpU in poliovirus-infected cells.

Authors:  N M Crawford; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

8.  NMR structure of the viral peptide linked to the genome (VPg) of poliovirus.

Authors:  Catherine H Schein; Numan Oezguen; David E Volk; Ravindranath Garimella; Aniko Paul; Werner Braun
Journal:  Peptides       Date:  2006-03-15       Impact factor: 3.750

9.  Novel, structure-based mechanism for uridylylation of the genome-linked peptide (VPg) of picornaviruses.

Authors:  Catherine H Schein; David E Volk; Numan Oezguen; Aniko Paul
Journal:  Proteins       Date:  2006-06-01

10.  The complete nucleotide sequence of a variant of Coxsackievirus A24, an agent causing acute hemorrhagic conjunctivitis.

Authors:  K Supanaranond; N Takeda; S Yamazaki
Journal:  Virus Genes       Date:  1992-04       Impact factor: 2.332

View more
  2 in total

1.  Designing multivalent immunogens for alphavirus vaccine optimization.

Authors:  C M Read; Kenneth Plante; Grace Rafael; Shannan L Rossi; Werner Braun; Scott C Weaver; Catherine H Schein
Journal:  Virology       Date:  2021-02-05       Impact factor: 3.513

Review 2.  Repurposing approved drugs on the pathway to novel therapies.

Authors:  Catherine H Schein
Journal:  Med Res Rev       Date:  2019-08-20       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.